NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT05041062 2024-01-03A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal MesotheliomaUniversity of ChicagoPhase 2 Completed2 enrolled 8 charts
NCT03241173 2022-09-27A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed52 enrolled 25 charts
NCT02716272 2021-02-10MAPS2Intergroupe Francophone de Cancerologie ThoraciquePhase 2 Completed125 enrolled